Literature DB >> 27029427

Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury.

Atsuko Kamijo-Ikemori1, Takeshi Sugaya2, Chihiro Hibi3, Takashi Nakamura3, Takayo Murase4, Tsuyoshi Oikawa5, Seiko Hoshino6, Mikako Hisamichi7, Kazuaki Hirata6, Kenjiro Kimura8, Yugo Shibagaki7.   

Abstract

The aim of the present study was to reveal the effect of a xanthine oxidoreductase (XOR) inhibitor, topiroxostat (Top), compared with another inhibitor, febuxostat (Feb), in an adenine-induced renal injury model. We used human liver-type fatty acid-binding protein (L-FABP) chromosomal transgenic mice, and urinary L-FABP, a biomarker of tubulointerstitial damage, was used to evaluate tubulointerstitial damage. Male transgenic mice (n = 24) were fed a 0.2% (wt/wt) adenine-containing diet. Two weeks after the start of this diet, renal dysfunction was confirmed, and the mice were divided into the following four groups: the adenine group was given only the diet containing adenine, and the Feb, high-dose Top (Top-H), and low-dose Top (Top-L) groups were given diets containing Feb (3 mg/kg), Top-H (3 mg/kg), and Top-L (1 mg/kg) in addition to adenine for another 2 wk. After withdrawal of the adenine diet, each medication was continued for 2 wk. Serum creatinine levels, the degree of macrophage infiltration, tubulointerstitial damage, renal fibrosis, urinary 15-F2t-isoprostane levels, and renal XOR activity were significantly attenuated in the kidneys of the Feb, Top-L, and Top-H groups compared with the adenine group. Serum creatinine levels in the Top-L and Top-H groups as well as renal XOR in the Top-H group were significantly lower than those in the Feb group. Urinary excretion of L-FABP in both the Top-H and Top-L groups was significantly lower than in the adenine and Feb groups. In conclusion, Top attenuated renal damage in an adenine-induced renal injury model.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  adenine; liver-type fatty acid-binding protein; topiroxostat; tubulointerstitial damage; xanthine oxidoreductase; xanthine oxidoreductase inhibitor

Mesh:

Substances:

Year:  2016        PMID: 27029427     DOI: 10.1152/ajprenal.00517.2015

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  8 in total

1.  Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Authors:  Takashi Wada; Tatsuo Hosoya; Daisuke Honda; Ryusuke Sakamoto; Kazutaka Narita; Tomomitsu Sasaki; Daisuke Okui; Kenjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2018-01-25       Impact factor: 2.801

2.  Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats.

Authors:  Yosuke Kawamorita; Takeshi Shiraishi; Yoshifuru Tamura; Takanori Kumagai; Shigeru Shibata; Yoshihide Fujigaki; Makoto Hosoyamada; Takahiko Nakagawa; Shunya Uchida
Journal:  Physiol Rep       Date:  2017-08

3.  Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report.

Authors:  Atsushi Tanaka; Tsukasa Nakamura; Eiichi Sato; Koichi Node
Journal:  Drugs R D       Date:  2017-03

4.  The serum amyloid A3 promoter-driven luciferase reporter mice is a valuable tool to image early renal fibrosis development and shows the therapeutic effect of glucosyl-hesperidin treatment.

Authors:  Thanutchaporn Kumrungsee; Taishi Kariya; Kotaro Hashimoto; Takayuki Koyano; Nao Yazawa; Takao Hashimoto; Yohei Sanada; Makoto Matsuyama; Yusuke Sotomaru; Hiroaki Sakurai; Fons A J van de Loo; Noriyuki Yanaka
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

5.  Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.

Authors:  Kazuomi Kario; Masafumi Nishizawa; Mari Kiuchi; Arihiro Kiyosue; Fumishi Tomita; Hiroshi Ohtani; Yasuhisa Abe; Hideyo Kuga; Satoshi Miyazaki; Takatoshi Kasai; Makiko Hongou; Takanori Yasu; Jin Kuramochi; Yoshihiro Fukumoto; Satoshi Hoshide; Ichiro Hisatome
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-01-05       Impact factor: 3.738

6.  SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure.

Authors:  Hsin-Jung Ho; Koichi Kikuchi; Daiki Oikawa; Shun Watanabe; Yoshitomi Kanemitsu; Daisuke Saigusa; Ryota Kujirai; Wakako Ikeda-Ohtsubo; Mariko Ichijo; Yukako Akiyama; Yuichi Aoki; Eikan Mishima; Yoshiaki Ogata; Yoshitsugu Oikawa; Tetsuro Matsuhashi; Takafumi Toyohara; Chitose Suzuki; Takehiro Suzuki; Nariyasu Mano; Yoshiteru Kagawa; Yuji Owada; Takane Katayama; Toru Nakayama; Yoshihisa Tomioka; Takaaki Abe
Journal:  Physiol Rep       Date:  2021-12

7.  Germ-Free Conditions Modulate Host Purine Metabolism, Exacerbating Adenine-Induced Kidney Damage.

Authors:  Eikan Mishima; Mariko Ichijo; Takeshi Kawabe; Koichi Kikuchi; Yukako Akiyama; Takafumi Toyohara; Takehiro Suzuki; Chitose Suzuki; Atsuko Asao; Naoto Ishii; Shinji Fukuda; Takaaki Abe
Journal:  Toxins (Basel)       Date:  2020-08-26       Impact factor: 4.546

8.  Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia.

Authors:  Tomohito Gohda; Naotake Yanagisawa; Maki Murakoshi; Seiji Ueda; Yuji Nishizaki; Shuko Nojiri; Yasuo Ohashi; Iwao Ohno; Yugo Shibagaki; Naohiko Imai; Satoshi Iimuro; Masanari Kuwabara; Hiroshi Hayakawa; Kenjiro Kimura; Tatsuo Hosoya; Yusuke Suzuki
Journal:  Front Med (Lausanne)       Date:  2021-07-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.